Needham Thinks OncoCyte’s Stock is Going to Recover

Needham analyst Michael Matson maintained a Buy rating on OncoCyte (OCXResearch Report) today and set a price target of $4.00. The company’s shares closed last Thursday at $1.40, close to its 52-week low of $1.22.

According to, Matson is a 4-star analyst with an average return of 6.8% and a 52.0% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

OncoCyte has an analyst consensus of Strong Buy, with a price target consensus of $3.80.

See the top stocks recommended by analysts >>

Based on OncoCyte’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $984K and GAAP net loss of $13.8 million. In comparison, last year the company earned revenue of $555K and had a GAAP net loss of $6.78 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.

Read More on OCX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More